{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:23:24Z","timestamp":1789741404566,"version":"4.0.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Zika virus, a previously neglected mosquito-borne virus, is prompting worldwide concern because of its connection with congenital defects, Guillain-Barr\u00e9 syndrome, meningoencephalitis and myelitis in infected individuals. However, no specific antiviral therapy is available at present. In this study, we investigated the in vitro susceptibility of geographically and temporally distinct Zika viruses against the RNA polymerase inhibitors, favipiravir (T-705) and ribavirin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The in vitro activity of each drug and a 1:1 mixture combination was assessed against five geographically and temporally distinct Zika strains by plaque reduction assay (PRA), the gold standard phenotypic method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We showed that both drugs exhibit in vitro inhibitory activity against five different Zika strains isolated in different years and continents, with mean 50% inhibitory concentration (IC\n                      <jats:sub>50<\/jats:sub>\n                      ) values of 35 \u00b114 and 35 \u00b120 \u03bcM, respectively, by PRA. We did not observe a synergistic effect when both drugs were combined at the equimolar concentration (IC\n                      <jats:sub>50<\/jats:sub>\n                      =33 \u00b111 \u03bcM).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results indicate that T-705 has the potential to be used in patients with complicated diseases and\/or those individuals presenting with significant comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3180","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T05:08:44Z","timestamp":1499749724000},"page":"613-618","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["<i>In vitro<\/i>\n                    Susceptibility of Geographically and Temporally Distinct Zika Viruses to Favipiravir and Ribavirin"],"prefix":"10.1177","volume":"22","author":[{"given":"Mariana","family":"Baz","sequence":"first","affiliation":[{"name":"Research Center in Infectious Diseases of the CHU of Qu\u00e9bec and Laval University, Qu\u00e9bec City, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goyette","sequence":"additional","affiliation":[{"name":"Research Center in Infectious Diseases of the CHU of Qu\u00e9bec and Laval University, Qu\u00e9bec City, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D","family":"Griffin","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P","family":"Kobinger","sequence":"additional","affiliation":[{"name":"Research Center in Infectious Diseases of the CHU of Qu\u00e9bec and Laval University, Qu\u00e9bec City, QC, Canada"},{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[{"name":"Research Center in Infectious Diseases of the CHU of Qu\u00e9bec and Laval University, Qu\u00e9bec City, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"bibr1-IMP3180","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.1.73-83.1998"},{"key":"bibr2-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(52)90042-4"},{"key":"bibr3-IMP3180","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805715"},{"key":"bibr4-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2014.04.008"},{"key":"bibr5-IMP3180","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760150192"},{"key":"bibr6-IMP3180","unstructured":"World Health Organization. Situation report. Zika virus microcephaly and Guillain-Barre syndrome. (Updated 10 March 2017. Accessed 25 April 2017.) Available from http:\/\/www.who.int\/emergencies\/zika-virus\/situation-report\/10-march-2017\/en\/."},{"key":"bibr7-IMP3180","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1604338"},{"key":"bibr8-IMP3180","unstructured":"World Health Organization. WHO director-general summarizes the outcome of the emergency committee regarding clusters of microcephaly and Guillain-Barre syndrome. (Accessed 2 February 2016.) Available from http:\/\/www.who.int\/mediacentre\/news\/statements\/2016\/emergency-committee-zika-microcephaly\/en."},{"key":"bibr9-IMP3180","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-07"},{"key":"bibr10-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.01.012"},{"key":"bibr11-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.07.009"},{"key":"bibr12-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.02.201"},{"key":"bibr13-IMP3180","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00709-16"},{"key":"bibr14-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.07.034"},{"key":"bibr15-IMP3180","unstructured":"ClinicalTrials.gov. Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults. 8 December 2013. (Accessed 15 September 2015.) Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008344."},{"key":"bibr16-IMP3180","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001967"},{"key":"bibr17-IMP3180","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004695"},{"key":"bibr18-IMP3180","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807650"},{"key":"bibr19-IMP3180","first-page":"452","volume":"29","author":"Cooper A.C.","year":"2003","journal-title":"Pediatr Nurs"},{"key":"bibr20-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.10.005"},{"key":"bibr21-IMP3180","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601023140104"},{"key":"bibr22-IMP3180","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00102-15"},{"key":"bibr23-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(80)90252-5"},{"key":"bibr24-IMP3180","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00327"},{"key":"bibr25-IMP3180","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03274-15"},{"key":"bibr26-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2016.08.015"},{"key":"bibr27-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.015"},{"key":"bibr28-IMP3180","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.5.865"},{"key":"bibr29-IMP3180","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.859-866.2000"},{"key":"bibr30-IMP3180","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71047-3"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3180","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:19Z","timestamp":1777380739000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.3851\/IMP3180"],"URL":"https:\/\/doi.org\/10.3851\/imp3180","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}